- Home
- MIRM vs OZKAP Comparison
MIRM vs OZKAP Comparison
Compare MIRM & OZKAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- OZKAP
- Stock Information
- Founded
- MIRM 2018
- OZKAP N/A
- Country
- MIRM United States
- OZKAP United States
- Employees
- MIRM N/A
- OZKAP 3028
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- OZKAP Major Banks
- Sector
- MIRM Health Care
- OZKAP Finance
- Exchange
- MIRM Nasdaq
- OZKAP Nasdaq
- Market Cap
- MIRM 1.9B
- OZKAP N/A
- IPO Year
- MIRM 2019
- OZKAP N/A
- Fundamental
- Price
- MIRM $40.80
- OZKAP $16.61
- Analyst Decision
- MIRM Strong Buy
- OZKAP
- Analyst Count
- MIRM 11
- OZKAP 0
- Target Price
- MIRM $58.55
- OZKAP N/A
- AVG Volume (30 Days)
- MIRM 438.4K
- OZKAP N/A
- Earning Date
- MIRM 05-07-2025
- OZKAP N/A
- Dividend Yield
- MIRM N/A
- OZKAP N/A
- EPS Growth
- MIRM N/A
- OZKAP N/A
- EPS
- MIRM N/A
- OZKAP N/A
- Revenue
- MIRM $336,888,000.00
- OZKAP N/A
- Revenue This Year
- MIRM $29.51
- OZKAP N/A
- Revenue Next Year
- MIRM $20.27
- OZKAP N/A
- P/E Ratio
- MIRM N/A
- OZKAP N/A
- Revenue Growth
- MIRM 80.76
- OZKAP N/A
- 52 Week Low
- MIRM $23.83
- OZKAP N/A
- 52 Week High
- MIRM $54.23
- OZKAP N/A
- Technical
- Relative Strength Index (RSI)
- MIRM 45.27
- OZKAP 54.64
- Support Level
- MIRM $38.22
- OZKAP $15.75
- Resistance Level
- MIRM $39.87
- OZKAP $16.53
- Average True Range (ATR)
- MIRM 2.27
- OZKAP 0.42
- MACD
- MIRM 0.23
- OZKAP 0.09
- Stochastic Oscillator
- MIRM 61.83
- OZKAP 90.53
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About OZKAP Bank OZK 4.625% Series A Non-Cumulative Perpetual Preferred Stock
Bank OZK is a bank holding company that owns and operates a community bank, Bank of the Ozarks. The bank operates offices in Arkansas, Georgia, Florida, North Carolina, Texas, California, New York and Mississippi. It provides a range of banking services which include deposit services such as checking, savings, money market, time deposit, and individual retirement accounts to loan services like real estate, consumer, commercial, and industrial loans. Apart from providing traditional banking products and services it also provides treasury management, trust and wealth management, financial planning, online banking, and other related services.